Clinical Scorecard: Upcoming Clinical Trial to Evaluate Two Therapeutics for Rapidly Expanding Ebola Outbreak

At a Glance

Key Highlights

• Current outbreak is the third largest on record with nearly 1,100 confirmed cases and over 275 deaths.
• Trial will evaluate the efficacy of remdesivir and MBP-134, both individually and in combination.
• MBP-134 may serve as both a treatment and prophylaxis, but only treatment will be tested in this trial.
• The trial aims to enroll around 1,000 participants due to the lower case fatality rate of Bundibugyo ebolavirus.
• Conducted by a consortium including WHO, DRC’s National Institute of Biomedical Research, and others.

Guideline-Based Recommendations

Diagnosis

• Confirm cases of Bundibugyo ebolavirus through appropriate laboratory testing.

Management

• Administer remdesivir and MBP-134 as part of the clinical trial for treatment.

Monitoring & Follow-up

• Monitor participants for safety and efficacy outcomes during the trial.

Risks

• Potential for lower case fatality rate may necessitate larger trial size.

Patient & Prescribing Data

Individuals exposed to Bundibugyo ebolavirus in outbreak areas.

No proven effective drugs or vaccines currently available for Bundibugyo ebolavirus.

Clinical Best Practices

• Engage with local NGOs for participant enrollment in clinical trials.
• Ensure robust monitoring and reporting of trial outcomes.

Related Resources & Content

• World Health Organization